Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2453
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAkgul, Ozgur-
dc.contributor.authorAkinci, Aysen-
dc.contributor.authorAltan, Lale-
dc.contributor.authorAltay, Zuhal-
dc.contributor.authorAtaman, Sebnem-
dc.contributor.authorAyhan, Figen-
dc.contributor.authorBal, Ajda-
dc.contributor.authorBirtane, Murat-
dc.contributor.authorBodur, Hatice-
dc.contributor.authorCapkin, Erhan-
dc.contributor.authorCerrahoglu, Lale-
dc.contributor.authorDuruoz, Mehmet Tuncay-
dc.contributor.authorGunaydin, Rezzan-
dc.contributor.authorGunendi, Zafer-
dc.contributor.authorGurer, Gulcan-
dc.contributor.authorKacar, Cahit-
dc.contributor.authorKaptanoglu, Ece-
dc.contributor.authorKaya, Taciser-
dc.contributor.authorKocabas, Hilal-
dc.contributor.authorKotevoglu, Nurdan-
dc.contributor.authorNas, Kemal-
dc.contributor.authorOzdemirel, Erhan-
dc.contributor.authorRezvani, Aylin-
dc.contributor.authorSen, Nesrin-
dc.contributor.authorSendur, Omer Faruk-
dc.contributor.authorSoy Bugdayci, Derya-
dc.contributor.authorSunar, Ismihan-
dc.contributor.authorSurmeli, Zuhre Sari-
dc.contributor.authorYalcin, Peyman-
dc.date.accessioned2022-08-17T05:56:48Z-
dc.date.available2022-08-17T05:56:48Z-
dc.date.issued2015-
dc.identifier.urihttp://doi.org/10.5606/ArchRheumatol.2015.5654-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2453-
dc.description.abstractObjectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey. Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected. Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same. Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.en_US
dc.language.isoengen_US
dc.publisherTURKISH LEAGUE AGAINST RHEUMATISMTALATPASA BULVARI DUMLUPINAR CAD 40 3 CEBECI DORTYOL, ANKARA 06100, TURKEYen_US
dc.relation.isversionof10.5606/ArchRheumatol.2015.5654en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectADALIMUMAB PLUS METHOTREXATEINHIBITOR TOFACITINIB CP-690,550NECROSIS-FACTOR INHIBITORSDOUBLE-BLINDINADEQUATE RESPONSESTRATEGY TRIALJAK INHIBITORTOCILIZUMAB MONOTHERAPYANKYLOSING-SPONDYLITISCOMBINATION ETANERCEPTen_US
dc.subjectBiologic disease modifying anti-rheumatic drugsrheumatoid arthritissynthetic disease modifying anti-rheumatic drugstreatment recommendationsen_US
dc.titleTurkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLARen_US
dc.typearticleen_US
dc.relation.journalARCHIVES OF RHEUMATOLOGYen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0001-6906-991Xen_US
dc.contributor.authorID0000-0002-1632-1621en_US
dc.contributor.authorID0000-0002-4435-5677en_US
dc.contributor.authorID0000-0002-8848-8420en_US
dc.contributor.authorID0000-0002-8911-6741en_US
dc.contributor.authorID0000-0003-3012-2968en_US
dc.contributor.authorID0000-0003-3570-3825en_US
dc.contributor.authorID0000-0003-3584-2788en_US
dc.contributor.authorID0000-0003-3584-2788en_US
dc.identifier.volume30en_US
dc.identifier.issue4en_US
dc.identifier.startpage271en_US
dc.identifier.endpage284en_US
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.